This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
The high-profile acquisition of Activision by Microsoft, which CRA Competition’s teams advised on was named overall Matter of the Year, as well as Matter of...
CRA’s Dr. Benno Buehler and Kilian Mueller show that several concerns over the European Commission’s proposal for a regulation on standard essential patents...
CRA is a proud sponsor of the event. Sam Marden is a panelist during the session titled “Exploring the Application of Recent Merger Control Developments to...
Raphaël De Coninck is a speaker on the panel on tools and practices for effective and timely management of merger cases, acting as a Non-Governmental Advisor...
